CNTX 2022

Drug Profile

CNTX 2022

Alternative Names: CNTX-2022; Lidocaine gel - Centrexion Therapeutics

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator Centrexion Therapeutics
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 09 Feb 2016 Centrexion Therapeutics terminates a phase I trial in Pain in Australia due to limited patient enrolment (NCT02679339)
  • 24 Sep 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top